PMID- 25851895
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150408
LR  - 20200929
IS  - 1738-6586 (Print)
IS  - 2005-5013 (Electronic)
IS  - 1738-6586 (Linking)
VI  - 11
IP  - 2
DP  - 2015 Apr
TI  - Granulocyte colony-stimulating factor for amyotrophic lateral sclerosis: a 
      randomized, double-blind, placebo-controlled study of Iranian patients.
PG  - 164-71
LID - 10.3988/jcn.2015.11.2.164 [doi]
AB  - BACKGROUND AND PURPOSE: The aim of this study was to determine the efficacy and 
      tolerability of granulocyte colony-stimulating factor (G-CSF) in subjects with 
      amyotrophic lateral sclerosis (ALS). METHODS: Forty subjects with ALS were 
      randomly assigned to two groups, which received either subcutaneous G-CSF (5 
      mug/kg/q12h) or placebo for 5 days. The subjects were then followed up for 3 
      months using the ALS Functional Rating Scale-Revised (ALSFRS-R), manual muscle 
      testing, ALS Assessment Questionnaire-40, and nerve conduction studies. 
      CD34+/CD133+ cell count and monocyte chemoattractant protein-1 (MCP-1) levels 
      were evaluated at baseline. RESULTS: The rate of disease progression did not 
      differ significantly between the two groups. The reduction in ALSFRS-R scores was 
      greater in female subjects in the G-CSF group than in their counterparts in the 
      placebo group. There was a trend toward a positive correlation between baseline 
      CSF MCP-1 levels and the change in ALSFRS-R scores in both groups (Spearman's 
      rho=0.370, p=0.070). CONCLUSIONS: With the protocol implemented in this study, 
      G-CSF is not a promising option for the treatment of ALS. Furthermore, it may 
      accelerate disease progression in females.
FAU - Amirzagar, Nasibeh
AU  - Amirzagar N
AD  - Iranian Center of Neurological Research, Imam Khomeini Hospital, Tehran 
      University of Medical Sciences, Tehran, Iran.
FAU - Nafissi, Shahriar
AU  - Nafissi S
AD  - Neurology Department, Tehran Shariati Hospital, University of Medical Sciences, 
      Tehran, Iran.
FAU - Tafakhori, Abbas
AU  - Tafakhori A
AD  - Iranian Center of Neurological Research, Imam Khomeini Hospital, Tehran 
      University of Medical Sciences, Tehran, Iran.
FAU - Modabbernia, Amirhossein
AU  - Modabbernia A
AD  - Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, 
      USA.
FAU - Amirzargar, Aliakbar
AU  - Amirzargar A
AD  - Department of Immunology, Faculty of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Ghaffarpour, Majid
AU  - Ghaffarpour M
AD  - Iranian Center of Neurological Research, Imam Khomeini Hospital, Tehran 
      University of Medical Sciences, Tehran, Iran.
FAU - Siroos, Bahaddin
AU  - Siroos B
AD  - Iranian Center of Neurological Research, Imam Khomeini Hospital, Tehran 
      University of Medical Sciences, Tehran, Iran.
FAU - Harirchian, Mohammad Hossein
AU  - Harirchian MH
AD  - Iranian Center of Neurological Research, Imam Khomeini Hospital, Tehran 
      University of Medical Sciences, Tehran, Iran. harirchn@hotmail.com.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - J Clin Neurol
JT  - Journal of clinical neurology (Seoul, Korea)
JID - 101252374
PMC - PMC4387482
OTO - NOTNLM
OT  - ALS Functional Rating Scale
OT  - CD34+/CD133+ cells
OT  - amyotrophic lateral sclerosis
OT  - compound motor action potential
OT  - granulocyte colony-stimulating factor
OT  - monocyte chemoattractant protein-1
COIS- Conflicts of Interest: The authors have no financial conflicts of interest.
EDAT- 2015/04/09 06:00
MHDA- 2015/04/09 06:01
PMCR- 2015/04/01
CRDT- 2015/04/09 06:00
PHST- 2014/09/15 00:00 [received]
PHST- 2014/11/18 00:00 [revised]
PHST- 2014/11/18 00:00 [accepted]
PHST- 2015/04/09 06:00 [entrez]
PHST- 2015/04/09 06:00 [pubmed]
PHST- 2015/04/09 06:01 [medline]
PHST- 2015/04/01 00:00 [pmc-release]
AID - 201503164 [pii]
AID - 10.3988/jcn.2015.11.2.164 [doi]
PST - ppublish
SO  - J Clin Neurol. 2015 Apr;11(2):164-71. doi: 10.3988/jcn.2015.11.2.164.